Hypofractionated Salvage Radiotherapy Holds Its Own After Prostatectomy
A phase III randomized trial in biochemical recurrence after radical prostatectomy found no 4-year advantage for hypofractionated salvage radiotherapy over the standard schedule, but the shorter course delivered comparable disease control and similar patient-reported quality of life. For men who have already been through surgery and now face a rising prostate-specific antigen, the result matters because salvage treatment is often chosen in a narrow window when microscopic disease may still be confined to the pelvis.
Investigators enrolled 316 patients with intermediate- to high-risk prostate cancer between 2019 and 2021 and assigned them to either 65 Gy in 26 fractions or 66 Gy in 33 fractions. Both approaches targeted the prostate bed, while elective pelvic nodal irradiation was left to the discretion of treating radiation oncologists. Intensity-modulated radiotherapy with daily image guidance provided the technical backbone for both arms, which keeps the comparison centered on fractionation rather than on a crude difference in delivery quality.
The trial asks a practical question that radiation oncologists confront constantly: can fewer, larger fractions preserve tumor control in the salvage setting without paying a toxicity penalty? In the postoperative pelvis, where bowel loops may settle closer to the radiation field and anatomy can shift from one day to the next, the answer depends not only on oncologic efficacy but also on how carefully the rectum and adjacent bowel are protected.
Disease Control Stayed Close Across Both Arms
At a median follow-up of 52.6 months, the 4-year biochemical progression-free survival rates were 80.1% with hypofractionated RT and 78.1% with conventional RT. The curves did not separate in a clinically persuasive way, and the study did not establish superiority for the shorter regimen. In the salvage setting, where the goal is to delay or prevent overt recurrence after a postoperative PSA rise, that kind of parity is meaningful.
Distant control also remained similar. The 4-year distant metastasis-free survival rates were 91.7% and 91.0% in the hypofractionated and conventional groups, respectively, and prostate cancer-specific survival was 100% in both arms. Those numbers suggest that, over the follow-up available, neither treatment schedule appeared to compromise the ability to suppress spread beyond the pelvis or to influence short-term prostate cancer mortality.
This was not a low-intensity cohort. Androgen deprivation therapy accompanied radiotherapy in 151 patients, or 51.2% of the trial population, and elective nodal irradiation was delivered in 202 patients, or 68.5%. The median pre-radiotherapy prostate-specific antigen level was 0.36 ng/mL, with an interquartile range of 0.24 to 0.49 ng/mL. Those baseline details matter because salvage radiotherapy outcomes are highly sensitive to PSA level at treatment start and to whether regional microscopic disease is addressed along with the prostate bed.
Rectal Toxicity Rose in the Shorter Schedule
A single-sentence reality check sits inside the toxicity data. The hypofractionated arm carried more grade 2 or higher gastrointestinal toxicity.
The 4-year cumulative incidence of grade 2 or higher GI toxicity was 7.9% with hypofractionated RT versus 0.7% with conventional RT. The excess toxicity appeared predominantly in patients who did not receive an endorectal balloon, and all cases had resolved by the last follow-up. That pattern is biologically plausible: larger dose fractions can intensify acute and subacute mucosal injury, and if the rectal wall is less consistently displaced away from the high-dose region, the bowel receives more clinically relevant exposure.
Rectal protection emerged as an important modifier of tolerability. Endorectal balloons were used in 186 men, or 63.1% of the cohort, and the toxicity signal clustered outside that group. In a postoperative setting where the rectum lies close to the prostate bed target, even modest improvements in reproducibility can alter whether a fractionated regimen is merely convenient or genuinely comfortable for the patient.
The report did not identify a meaningful difference in patient-reported quality-of-life outcomes. That aligns with the broader clinical picture: a slightly higher GI toxicity burden does not necessarily translate into sustained patient-perceived harm when events are resolved and when modern image guidance keeps treatment delivery tight. Still, the difference in GI toxicity keeps rectal sparing strategies squarely in view if hypofractionated salvage RT is adopted more broadly.
What the Trial Means for Salvage Practice
The study supports hypofractionated salvage RT as a viable alternative rather than a more effective one. For clinicians, the immediate advantage is logistical: fewer treatment visits can ease the burden on patients who are often older, may be traveling for daily therapy, and are already recovering from surgery while navigating the anxiety of a rising PSA.
Yet convenience cannot outrun toxicity. The higher GI event rate in the hypofractionated arm suggests that the therapeutic ratio may depend on how consistently rectal displacement is achieved, particularly when elective nodal treatment is added and the pelvic field becomes more anatomically complex. In practical terms, this points to a need for careful patient selection, meticulous planning, and serious attention to motion management rather than a blanket switch in fractionation.
The trial also reinforces an important principle in postoperative prostate radiotherapy: biochemical recurrence is not a single biological state. Some patients harbor disease confined to the fossa, some have occult nodal involvement, and many receive concurrent androgen deprivation therapy. A regimen that performs well across that mix is useful, but it still leaves open the question of whether certain subgroups derive more benefit from one fractionation approach or from more aggressive rectal-sparing techniques.
Endorectal Balloon Use May Shape Future Fractionation Choices
The most actionable clue in the trial is not the survival data alone. It is the interaction between fraction size and rectal protection.
The predominance of resolved GI toxicity in patients without an endorectal balloon suggests that this device may help preserve the tolerability of hypofractionated salvage treatment. Whether that protection is strong enough to justify routine use, and whether it meaningfully reduces late bowel injury beyond the follow-up reported here, remains unsettled. A dedicated comparison of balloon use, rather than an indirect signal embedded within a fractionation trial, would answer that question more cleanly.
For now, the evidence supports two conclusions at once. First, hypofractionated salvage radiotherapy did not outperform conventional treatment for biochemical progression-free survival at 4 years. Second, it delivered broadly comparable oncologic outcomes and quality of life, with a modest GI toxicity tradeoff that appears tied to rectal setup and protection. In a postoperative disease state where every fraction is being asked to do work against microscopic residual cancer, that balance is clinically acceptable for many patients, but not all delivery strategies are equally forgiving.